Literature DB >> 2846282

Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain.

M J Gething1, B Adler, J A Boose, R D Gerard, E L Madison, D McGookey, R S Meidell, L M Roman, J Sambrook.   

Abstract

The heavy chain of tissue plasminogen activator (t-PA) consists of four domains [finger, epidermal-growth-factor (EGF)-like, kringle 1 and kringle 2] that are homologous to similar domains present in other proteins. To assess the contribution of each of the domains to the biological properties of the enzyme, site-directed mutagenesis was used to generate a set of mutants lacking sequences corresponding to the axons encoding the individual structural domains. The mutant proteins were assayed for their ability to hydrolyze artificial and natural substrates in the presence and absence of fibrin, to bind to lysine-Sepharose and to be inhibited by plasminogen activator inhibitor-1. All the deletion mutants exhibit levels of basal enzymatic activity very similar to that of wild-type t-PA assayed in the absence of fibrin. A mutant protein lacking the finger domain has a 2-fold higher affinity for plasminogen than wild-type t-PA, while the mutant that lacks both finger and EGF-like domains is less active at low concentrations of plasminogen. Mutants lacking both kringles neither bind to lysine-Sepharose nor are stimulated by fibrin. However, mutants containing only one kringle (either kringle 1 or kringle 2) behave indistinguishably from one another and from the wild-type protein. We conclude that kringle 1 and kringle 2 are equivalent in their ability to mediate stimulation of catalytic activity by fibrin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846282      PMCID: PMC457063          DOI: 10.1002/j.1460-2075.1988.tb03127.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  56 in total

1.  The human tissue plasminogen activator gene.

Authors:  S J Degen; B Rajput; E Reich
Journal:  J Biol Chem       Date:  1986-05-25       Impact factor: 5.157

2.  lin-12, a nematode homeotic gene, is homologous to a set of mammalian proteins that includes epidermal growth factor.

Authors:  I Greenwald
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

3.  Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants.

Authors:  C M Hekman; D J Loskutoff
Journal:  J Biol Chem       Date:  1985-09-25       Impact factor: 5.157

4.  Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats.

Authors:  K A Wharton; K M Johansen; T Xu; S Artavanis-Tsakonas
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

5.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

Authors:  M Hoylaerts; D C Rijken; H R Lijnen; D Collen
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

6.  Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator.

Authors:  D C Rijken; M Hoylaerts; D Collen
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

7.  Studies on the kinetics of plasminogen activation by tissue plasminogen activator.

Authors:  M Rånby
Journal:  Biochim Biophys Acta       Date:  1982-06-24

8.  Domain structure of hamster plasma fibronectin. Isolation and characterization of four functionally distinct domains and their unequal distribution between two subunit polypeptides.

Authors:  K Sekiguchi; M Fukuda; S Hakomori
Journal:  J Biol Chem       Date:  1981-06-25       Impact factor: 5.157

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.

Authors:  D C Rijken; D Collen
Journal:  J Biol Chem       Date:  1981-07-10       Impact factor: 5.157

View more
  17 in total

1.  Marfan syndrome: defective synthesis, secretion, and extracellular matrix formation of fibrillin by cultured dermal fibroblasts.

Authors:  D M Milewicz; R E Pyeritz; E S Crawford; P H Byers
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

Review 2.  The plasminogen activator/plasmin system.

Authors:  J D Vassalli; A P Sappino; D Belin
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

3.  A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.

Authors:  M S Runge; T Quertermous; P J Zavodny; T W Love; C Bode; M Freitag; S Y Shaw; P L Huang; C C Chou; D Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 4.  Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.

Authors:  R Fears
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

5.  Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.

Authors:  E L Madison; E J Goldsmith; R D Gerard; M J Gething; J F Sambrook; R S Bassel-Duby
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

6.  Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.

Authors:  O F Wagner; C de Vries; C Hohmann; H Veerman; H Pannekoek
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

7.  Calnexin and calreticulin bind to enzymically active tissue-type plasminogen activator during biosynthesis and are not required for folding to the native conformation.

Authors:  S Allen; N J Bulleid
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

8.  Cell-free synthesis of enzymically active tissue-type plasminogen activator. Protein folding determines the extent of N-linked glycosylation.

Authors:  N J Bulleid; R S Bassel-Duby; R B Freedman; J F Sambrook; M J Gething
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

9.  Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.

Authors:  J H Wu; S L Diamond
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

10.  Muscle-specific trk-related receptor with a kringle domain defines a distinct class of receptor tyrosine kinases.

Authors:  C G Jennings; S M Dyer; S J Burden
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.